115 related articles for article (PubMed ID: 15231655)
41. Prospective study of mutant frequencies at the hprt and T-cell receptor gene loci in pediatric cancer patients during chemotherapy.
Sawada M; Kubota M; Lin YW; Watanabe K; Koishi S; Usami I; Akiyama Y; Matsumura T; Furusho K
Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):711-7. PubMed ID: 9718224
[TBL] [Abstract][Full Text] [Related]
42. Effect of chronic azathioprine treatment on germ-line transmission of Hprt mutation in mice.
Bendre SV; Shaddock JG; Dobrovolsky VN; Albertini RJ; Heflich RH
Environ Mol Mutagen; 2007 Dec; 48(9):744-53. PubMed ID: 18008354
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
44. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
[TBL] [Abstract][Full Text] [Related]
45. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
[TBL] [Abstract][Full Text] [Related]
46. Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial.
Le QH; Thomas X; Ecochard R; Iwaz J; Lhéritier V; Michallet M; Fiere D
Cancer; 2007 May; 109(10):2058-67. PubMed ID: 17407135
[TBL] [Abstract][Full Text] [Related]
47. [Herpes zoster-associated morbidity in children undergoing chemotherapy for acute lymphoblastic leukaemia].
Sørensen GV; Helgestad J; Rosthøj S
Ugeskr Laeger; 2009 Nov; 171(46):3350-4. PubMed ID: 19925740
[TBL] [Abstract][Full Text] [Related]
48. Second malignant neoplasms in childhood acute lymphoblastic leukemia: primitive neuroectodermal tumor of the chest wall with germline p53 mutation as a second malignant neoplasm.
Suarez CR; Bertolone SJ; Raj AB; Coventry S
Am J Hematol; 2004 May; 76(1):52-6. PubMed ID: 15114597
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
50. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database.
Högler W; Wehl G; van Staa T; Meister B; Klein-Franke A; Kropshofer G
Pediatr Blood Cancer; 2007 Jan; 48(1):21-7. PubMed ID: 16317756
[TBL] [Abstract][Full Text] [Related]
51. [The function of the immune system after the treatment of pediatric malignant diseases].
Gadó J; Schlick B; Bárány O; Németh J; Müller J; Csóka M; Constantin T; Vonnák E; Böcskei R; Hauser P; Kovács G
Orv Hetil; 2006 Sep; 147(36):1731-8. PubMed ID: 17087017
[TBL] [Abstract][Full Text] [Related]
52. [Relationship between body mass index and leptin levels in children treated for acute lymphoblastic leukemia during and after maintenance therapy].
Muszyńska-Rosłan K; Krawczuk-Rybak M; Topczewska M; Sawicka-Zukowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(2):91-5. PubMed ID: 16813712
[TBL] [Abstract][Full Text] [Related]
53. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
Waber DP; Turek J; Catania L; Stevenson K; Robaey P; Romero I; Adams H; Alyman C; Jandet-Brunet C; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2007 Nov; 25(31):4914-21. PubMed ID: 17971588
[TBL] [Abstract][Full Text] [Related]
54. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
55. Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.
Buizer AI; De Sonneville LM; van den Heuvel-Eibrink MM; Njiokiktjien C; Veerman AJ
J Int Neuropsychol Soc; 2005 Sep; 11(5):554-65. PubMed ID: 16212682
[TBL] [Abstract][Full Text] [Related]
56. Gestational age and gender-specific in utero V(D)J recombinase-mediated deletions.
Yoshioka M; O'Neill JP; Vacek PM; Finette BA
Cancer Res; 2001 Apr; 61(8):3432-8. PubMed ID: 11309304
[TBL] [Abstract][Full Text] [Related]
57. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
58. [Bone mineral density in children before and after completion of cancer treatment].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M; Kaczmarski M; Piotrowska-Jastrzebska J
Pol Merkur Lekarski; 2004 Jul; 17(97):37-42. PubMed ID: 15559608
[TBL] [Abstract][Full Text] [Related]
59. High-risk childhood acute lymphoblastic leukemia in China: factors influencing the treatment and outcome.
Luo XQ; Ke ZY; Huang LB; Guan XQ; Zhang YC; Zhang XL
Pediatr Blood Cancer; 2009 Feb; 52(2):191-5. PubMed ID: 18989886
[TBL] [Abstract][Full Text] [Related]
60. Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments.
Alikasifoglu A; Yetgin S; Cetin M; Tuncer M; Gumruk F; Gurgey A; Yordam N
Am J Hematol; 2005 Oct; 80(2):113-8. PubMed ID: 16184587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
